(MedPage Today) — An FDA panel said that trial data did not provide substantial evidence showing that investigational deramiocel was effective in treating cardiomyopathy among patients with Duchenne muscular dystrophy.
In a 9-3 vote, the FDA…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
